m+Medelevator.RU
← Поиск публикаций
Frontiers in microbiology · 2026

Phage therapy against methicillin-resistant Staphylococcus pseudintermedius: a novel strategy for canine pyoderma.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Feng Xiancheng, Du Qingjie, Wang Keyi, Chen Ruiqi, Ma Rui, Xing Yunping, Lei Xinyue, Wang Miao, Dai Pengxiu, Zhang Xinke

Аннотация

INTRODUCTION: Methicillin-resistant Staphylococcus pseudintermedius (MRSP) poses a major public health challenge due to its multidrug resistance. Phages represent an innovative therapeutic strategy with considerable potential against drug-resistant bacterial infections.

METHODS: In this study, dogs clinically diagnosed with pyoderma were recruited to establish an epidemiological dataset, and multidrug-resistant S. pseudintermedius strains (including 6 MRSP isolates) were obtained from bacterial cultures. Three high-efficiency lytic phages were isolated using these MRSP strains as hosts and characterized. The combined efficacy of phages and antibiotics was evaluated in a pyoderma model via clinical scoring, histopathological examination, and tissue bacterial load quantification.

RESULTS: Notably, these phages enhanced MRSP susceptibility to antibiotics, with genomic and proteomic analyses identifying key mediators of phage-mediated S. pseudintermedius lysis. The phage-antibiotic combination exhibited the most significant therapeutic effect on pyoderma, followed by the phage-only group. In contrast, the antibiotic-only group showed no significant improvement compared to the control group, with both yielding poor outcomes.

DISCUSSION: This study provides a promising therapeutic strategy for the clinical management of canine pyoderma in veterinary medicine and offers valuable insights for safeguarding public health security.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты